UY33191A - Derivados de pirazina - Google Patents

Derivados de pirazina

Info

Publication number
UY33191A
UY33191A UY0001033191A UY33191A UY33191A UY 33191 A UY33191 A UY 33191A UY 0001033191 A UY0001033191 A UY 0001033191A UY 33191 A UY33191 A UY 33191A UY 33191 A UY33191 A UY 33191A
Authority
UY
Uruguay
Prior art keywords
amino
formula
pharmaceutically acceptable
derivatives
pirazine
Prior art date
Application number
UY0001033191A
Other languages
English (en)
Inventor
Feng Tao
Hitesh Jayantilal Sanganee
Wada Hiroki
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY33191A publication Critical patent/UY33191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a derivados de pirazina de Fórmula I o sales farmacéuticamente aceptables de los mismos; en donde cada uno de n, m y R tiene uno de los significados definidos anteriormente en la presente en la memoria descriptiva; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para su uso en el tratamiento de trastornos o afecciones óseos. De acuerdo con un aspecto adicional de la invención se proporciona un derivado de pirazina de Fórmula I, que es 3-amino-6-(4-{3-[(3-metoxipropil)amino]propil}fenil)-Npiridin-3-ilpirazina-2-carboxamida; o una sal farmacéuticamente aceptable del mismo.
UY0001033191A 2010-01-19 2011-01-19 Derivados de pirazina UY33191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29619610P 2010-01-19 2010-01-19

Publications (1)

Publication Number Publication Date
UY33191A true UY33191A (es) 2011-08-31

Family

ID=43743548

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033191A UY33191A (es) 2010-01-19 2011-01-19 Derivados de pirazina

Country Status (14)

Country Link
US (2) US8198285B2 (es)
EP (1) EP2526097A1 (es)
JP (1) JP2013517321A (es)
KR (1) KR20120120307A (es)
CN (1) CN102812017A (es)
AR (1) AR079945A1 (es)
AU (1) AU2011208530A1 (es)
BR (1) BR112012017884A2 (es)
CA (1) CA2786520A1 (es)
MX (1) MX2012008328A (es)
RU (1) RU2012135093A (es)
TW (1) TW201130814A (es)
UY (1) UY33191A (es)
WO (1) WO2011089416A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2714677T3 (pl) * 2011-05-23 2019-02-28 Merck Patent Gmbh Pochodne pirydynowe i pirazynowe
PT2970890T (pt) 2013-03-14 2020-04-24 Massachusetts Inst Technology Composições e métodos para expansão e cultura de células estaminais epiteliais
KR20230019500A (ko) 2014-09-03 2023-02-08 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
CA3048220A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
NZ514583A (en) 2000-02-05 2004-05-28 Vertex Pharma Pyrazole compositions useful as inhibitors of ERK
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2003235798A1 (en) 2002-01-10 2003-07-24 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
ATE346070T1 (de) 2002-03-05 2006-12-15 Lilly Co Eli Purinderivate als kinaseinhibitoren
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
BRPI0408251A (pt) 2003-03-11 2006-03-01 Pfizer Prod Inc compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
AU2004274861A1 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
MXPA05013637A (es) 2003-08-13 2006-02-24 Chiron Corp Inhibidores gsk-3 y usos de los mismos.
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20050064044A1 (en) 2003-09-19 2005-03-24 Georges Rawadi GSK-3beta inhibitors in the treatment of bone-related diseases
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYL AMIDES AS MODULATORS OF GLUTAMATE METABOTROPIC REPEATER-5
TW200800203A (en) * 2006-03-08 2008-01-01 Astrazeneca Ab New use
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
RU2011123647A (ru) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, полезные в качестве ингибиторов atr киназы

Also Published As

Publication number Publication date
AU2011208530A1 (en) 2012-08-09
US8198285B2 (en) 2012-06-12
US20120022082A1 (en) 2012-01-26
JP2013517321A (ja) 2013-05-16
EP2526097A1 (en) 2012-11-28
KR20120120307A (ko) 2012-11-01
BR112012017884A2 (pt) 2019-09-24
CA2786520A1 (en) 2011-07-28
RU2012135093A (ru) 2014-03-10
WO2011089416A1 (en) 2011-07-28
CN102812017A (zh) 2012-12-05
MX2012008328A (es) 2012-08-08
US20130123275A1 (en) 2013-05-16
AR079945A1 (es) 2012-02-29
TW201130814A (en) 2011-09-16

Similar Documents

Publication Publication Date Title
UY33191A (es) Derivados de pirazina
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201591195A1 (ru) Новые хинолоновые производные
NZ725008A (en) Compounds for treating spinal muscular atrophy
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
CO7160104A2 (es) Inhibidores de virus de hepatitis c
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
BR112013000059A2 (pt) derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191121